newsfilter
← Latest News
GlobeNewswire·

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

  • Cogent Biosciences reported Q2 2026 financial results with a pro forma cash balance of $865.9 million, sufficient to fund operations into late 2028.
  • The company submitted a New Drug Application for bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) on June 30, 2026.
  • FDA acceptance of the bezuclastinib NDA for Gastrointestinal Stromal Tumors (GIST) with priority review was announced.
  • PDUFA dates are set for November 30, 2026, for GIST approval, December 30, 2026, for Non-AdvSM approval, and the AdvSM NDA is under review.
  • Clinical data from the Phase 3 PEAK trial showed bezuclastinib plus sunitinib reduced the risk of disease progression or death by 50% compared to sunitinib monotherapy in GIST patients.
  • The PEAK trial demonstrated a median progression-free survival of 16.5 months for the bezuclastinib combination versus 9.2 months for sunitinib monotherapy.
  • An extension cohort of the PEAK trial investigating bezuclastinib in first-line GIST patients with KIT exon 9 mutations has been initiated.
  • Bezuclastinib showed a 65% overall response rate in the pivotal APEX trial for Systemic Mastocytosis patients as of March 31, 2026.
  • Enrollment in the SUMMIT extension trial for the "avapritinib switch" program was completed, with preliminary results expected by the end of 2026.
  • Cogent completed onboarding of its integrated business team, including clinical account managers, patient access navigators, and patient educators.
  • Research and development expenses increased to $70.8 million in Q2 2026 from $62.2 million in Q2 2025, driven by clinical program costs.
  • General and administrative expenses rose to $31.8 million in Q2 2026 from $13.4 million in Q2 2025, primarily due to commercial readiness investments.
  • The company reported a net loss of $96.4 million for Q2 2026 compared to $73.5 million for the same period in 2025.
  • Inducement equity awards comprising 226,700 options and 189,700 RSUs were granted to 59 new employees on August 4-10, 2026.
  • Plans include submitting Investigational New Drug applications for CGT1815 (pan-KRAS(ON) inhibitor) and CGT1145 (JAK2 V617F inhibitor).
  • Dose escalation for CGT4255, a mutant ErbB2 inhibitor, is scheduled for completion.